Zanzalintinib

Generic Name: Zanzalintinib

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₂₅FN_₄O_₅

CAS Number: 2367004-54-2

Unique Ingredient Identifier: KC2JC2ZA04

Clinical Trials

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Phase 1

Not yet recruiting

Conditions: Metastatic Soft-tissue Sarcoma

Interventions: Drug: Zanzalintinib
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2025-05-13

Last Posted Date: 2025-05-13

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 18

Registration Number: NCT06968988

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Phase 1

Not yet recruiting

Conditions: Hepatic Impairment
Moderate Hepatic Impairment

Interventions: Drug: Zanzalintinib

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-08

Lead Sponsor: Exelixis

Target Recruit Count: 20

Registration Number: NCT06962332

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Phase 2

Not yet recruiting

Conditions: Neoadjuvant Treatment
Thyroid Cancer

Interventions: Drug: Zanzalintinib

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT06959511

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Phase 2

Not yet recruiting

Conditions: Locally Advanced Differentiated Thyroid Gland Carcinoma
Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma
Locally Advanced Thyroid Gland Follicular Carcinoma
Locally Advanced Thyroid Gland Oncocytic Carcinoma
Metastatic Thyroid Gland Oncocytic Carcinoma
Locally Advanced Thyroid Gland Papillary Carcinoma
Metastatic Differentiated Thyroid Gland Carcinoma
Metastatic Poorly Differentiated Thyroid Gland Carcinoma
Metastatic Thyroid Gland Follicular Carcinoma
Metastatic Thyroid Gland Papillary Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Survey Administration
Procedure: X-Ray Imaging
Drug: Zanzalintinib

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: Northwestern University

Target Recruit Count: 33

Registration Number: NCT06959641

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Phase 1

Not yet recruiting

Conditions: Advanced Leiomyosarcoma
Adipocytic Sarcoma
Advanced Liposarcoma

Interventions: Drug: Zanzalintinib
Drug: Eribulin

First Posted Date: 2025-05-04

Last Posted Date: 2025-05-04

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 18

Registration Number: NCT06957431

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Phase 2

Not yet recruiting

Conditions: Pancreatic Neuroendocrine Tumor (pNET)
Extra-Pancreatic Neuroendocrine Tumor (epNET)

Interventions: Drug: Zanzalintinib
Drug: Everolimus

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-24

Lead Sponsor: Exelixis

Target Recruit Count: 440

Registration Number: NCT06943755

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Phase 1

Not yet recruiting

Conditions: Germ Cell Tumor

Interventions: Drug: Zanzalintinib
Drug: Etoposide Capsule

First Posted Date: 2025-04-22

Last Posted Date: 2025-04-22

Lead Sponsor: Indiana University

Target Recruit Count: 38

Registration Number: NCT06937866

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Phase 2

Not yet recruiting

Conditions: High Grade Neuroendocrine Neoplasms

Interventions: Drug: Zanzalintinib

First Posted Date: 2025-04-14

Last Posted Date: 2025-04-14

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 32

Registration Number: NCT06926634

Locations: 🇺🇸
Mayo Clinic - Rochester, Rochester, Minnesota, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Phase 1

Not yet recruiting

Conditions: Head and Neck Neoplasms
Carcinoma, Squamous Cell
Neoplasm Recurrence, Local
Neoplasm Metastasis
Recurrent Squamous Cell Carcinoma
Metastatic Squamous Cell Carcinoma

Interventions: Drug: Zanzalintinib
Drug: Cetuximab
Drug: Pembrolizumab

First Posted Date: 2025-04-04

Last Posted Date: 2025-04-08

Lead Sponsor: University of Chicago

Target Recruit Count: 36

Registration Number: NCT06912087

Locations: 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Phase 1

Not yet recruiting

Conditions: Anaplastic Thyroid Cancer
Thyroid Cancer
BRAF Mutation-Related Tumors

Interventions: Biological: Cemiplimab
Drug: XL092

First Posted Date: 2025-03-30

Last Posted Date: 2025-05-06

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT06902376

Locations: 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy